- Home
- ABSI vs AQST Comparison
ABSI vs AQST Comparison
Compare ABSI & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABSI
- AQST
- Stock Information
- Founded
- ABSI 2011
- AQST 2004
- Country
- ABSI United States
- AQST United States
- Employees
- ABSI N/A
- AQST N/A
- Industry
- ABSI Biotechnology: Pharmaceutical Preparations
- AQST Biotechnology: Pharmaceutical Preparations
- Sector
- ABSI Health Care
- AQST Health Care
- Exchange
- ABSI Nasdaq
- AQST Nasdaq
- Market Cap
- ABSI 318.2M
- AQST 285.4M
- IPO Year
- ABSI 2021
- AQST 2018
- Fundamental
- Price
- ABSI $4.35
- AQST $2.97
- Analyst Decision
- ABSI Strong Buy
- AQST Strong Buy
- Analyst Count
- ABSI 7
- AQST 8
- Target Price
- ABSI $8.57
- AQST $10.38
- AVG Volume (30 Days)
- ABSI 7.6M
- AQST 1.4M
- Earning Date
- ABSI 03-20-2025
- AQST 03-04-2025
- Dividend Yield
- ABSI N/A
- AQST N/A
- EPS Growth
- ABSI N/A
- AQST N/A
- EPS
- ABSI N/A
- AQST N/A
- Revenue
- ABSI $4,207,000.00
- AQST $58,900,000.00
- Revenue This Year
- ABSI $8.57
- AQST $18.44
- Revenue Next Year
- ABSI $169.72
- AQST N/A
- P/E Ratio
- ABSI N/A
- AQST N/A
- Revenue Growth
- ABSI N/A
- AQST 22.56
- 52 Week Low
- ABSI $2.45
- AQST $2.24
- 52 Week High
- ABSI $6.72
- AQST $6.23
- Technical
- Relative Strength Index (RSI)
- ABSI 66.14
- AQST 34.27
- Support Level
- ABSI $3.40
- AQST $2.87
- Resistance Level
- ABSI $4.01
- AQST $3.17
- Average True Range (ATR)
- ABSI 0.43
- AQST 0.14
- MACD
- ABSI 0.07
- AQST 0.02
- Stochastic Oscillator
- ABSI 97.13
- AQST 9.30
About ABSI Absci Corporation
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Sympazan Oral Film, Suboxone Sublingual Film, Exservan Oral Film, and Zuplenz. The product pipeline includes Libervant Buccal Film, AQST-108, and AQST-305. The majority of its revenue comes from the United States.